Tirzepatide is one of the new medications for the treatment of obesity. In clinical research people treated with Tirzepatide have weight loss up to 21%. But there is only a little bit of research showing the effect of Tirzepatide in clinical practice.

In this retrospective observational study the investigators will evaluate the effectiveness of tirzepatide in routine clinical practice among adults with obesity in the Netherlands.The main questions it aims to answer are:

• How much weight do patients lose after six months of treatment with tirzepatide combined with lifestyle coaching?
• How is the medication dosed in daily practice? Researchers will use data from electronic health records of patients in multiple outpatient locations of the Dutch Obesity Clinic (NOK, Nederlandse Obesitas Kliniek).

Inclusion Criteria:

• Adults (age ≥18 years old)
• A BMI of ≥ 30 kg/m2 or a BMI ≥ 27 kg/m2 with at least one obesity complication (e.g., hypertension, dyslipidaemia)

Exclusion Criteria:

• Pregnant women or pregnancy during treatment
• Previously treated for obesity (with pharmacotherapy, endoscopic treatment or metabolic-bariatric surgery)
• Patients with diabetes

Outpatient clinic